Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Therapeutic Development Suppliers Serving Europe
114 companies found
based inScandicci (FI), ITALY
Molteni Therapeutics is an Italian product-driven spin-off company of Molteni Farmaceutici a private–owned pharmaceutical firm based in Florence since 1892, dedicated to the development of innovative Medical Devices mainly based on the Photo Dynamic ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 ...
based inGijón, SPAIN
Our mission is to develop novel technologies and next generation live biotherapeutic products providing innovative solutions to health care by harnessing the treasure of the human microbiota. We are developing a novel class biotherapeutic products ...
Microviable Therapeutics is developing novel technologies and next generation biotherapeutic products by harnessing the treasure of the human microbiota generating innovative solutions that enable to address unmet ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inGhent, BELGIUM
ExeVir is a clinical stage company developing single-domain antibody-based therapies that help patients ward off viral infections. Our lead candidate XVR011 is in accelerated development as a COVID-19 ...
based inMunich, GERMANY
Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic ...
based inVienna, AUSTRIA
Aposcience AG is a worldwide innovation leader in the field of regenerative medicine. Regenerative medicine has the potential to transform the treatment for diseases with high medical need, as the tissues afflicted by the disease process can be ...
based inEmeryville, CALIFORNIA (USA)
Nutcracker Therapeutics is an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designed to enable the advancement of RNA-based treatments for as many diseases as possible, as fast as possible. ...
based inSchlieren, SWITZERLAND
We want to empower people to deal with their malignant cells through their own immune system just like we deal with viral infections. Today’s cancer immunotherapies are powerful but, to the detriment of their effect, not very tumor-selective. ...
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. ...
based inBasel, SWITZERLAND
We are a Biologics CDMO (Contract Development and Manufacturing Organization) offering our clients more than just development and manufacturing. In everything we do, we go one step beyond expectations. We enable our customers to exceed their goals ...
An extremely productive and stable CHO-based expression system for biopharmaceuticals. CHOvolution® is a CHO-K1 based expression platform that can be used for a broad range of applications, from non-GMP R&D testing to GMP development and ...
based inBoca Raton, FLORIDA (USA)
Entero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. At the core of its research are three proprietary technologies. Latiglutenase is an ...
Latiglutenase, known as IMGX003, is an orally administered formulation comprising two recombinant proteases specifically targeting gluten proteins. It works by breaking down these proteins into smaller, non-reactive fragments, offering an adjunctive ...
based inBoston, MASSACHUSETTS (USA)
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — ...
Vertex is focused on discovering, developing and commercializing innovative medicines so people with serious diseases can lead better lives. Our scientists don’t see the impossible as an obstacle; they see it as a good place to start. These ...
based inPozuelo de Alarcón, SPAIN
We are a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Our operations encompass the marketing of both our own and licensed products and the provision of services, such ...
based inPrinceton, NEW JERSEY (USA)
DDi is an innovative Technology partner for BioPharma and Medical Device companies. DDi has built its competency with a unique blend of functional / domain expertise to serve the technology needs of this industry. We serve Clinical, Regulatory, and ...
based inElkridge, MARYLAND (USA)
Latham BioPharm Group (LBG) is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development ...
based inSolna, SWEDEN
Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
We believe our IntelliSelect® Technology platforms reduce the risk of missing novel solutions and increase the quality and differentiation of antibodies, to identify product candidates with the most desirable drug-like ...
based inCarlsbad, CALIFORNIA (USA)
ScienCell Research Laboratories is an expanding biotechnology company established in 1999. Our mission is to research and develop cell products for experimental use. ScienCell provides a variety of high quality normal human and animal cells, cell ...
based inStockholm, SWEDEN
BioArctic is a Swedish research intensive biopharma company aimed at developing new treatments that address the causes of disorders that affect the Central Nervous System. These types of treatments are commonly referred to as disease modifiers. They ...
BioArctic has developed a technology platform that has proven to be successful when the company’s first drug candidate was developed, the antibody BAN2401 for Alzheimer´s disease. Our mission is to improve quality of life for patients ...
based inCranbury, NEW JERSEY (USA)
Advancing an integrated pipeline of genetic therapies that correct the root cause of complex and rare life-threatening childhood disorders. Our mission is to develop first-in-class and best-in-class, curative gene therapies for patients with ...
Rocket’s Research and Discovery group in the Cranbury, New Jersey facility utilizes approximately 20,000 square feet of state-of-the-art laboratories for designing, optimizing and advancing candidate therapeutics to clinical ...